CRC
IOVA icon

Curi RMB Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Curi RMB Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,092
Closed -$42.4K – 942
2026
Q1 		$42.4K Buy
+12,092
New +$38.7K ﹤0.01% 864
2025
Q2 		– Sell
-157,696
Closed -$525K – 671
2025
Q1 		$525K Buy
157,696
+49,059
+45% +$253K 0.01% 381
2024
Q4 		$804K Hold
108,637
– – 0.02% 360
2024
Q3 		$1.02M Buy
108,637
+36,117
+50% +$342K 0.02% 337
2024
Q2 		$582K Sell
72,520
-250
-0.3% -$2.68K 0.01% 399
2024
Q1 		$1.08M Buy
72,770
+1,953
+3% +$22.7K 0.02% 337
2023
Q4 		$576K Buy
70,817
+1,000
+1% +$5.23K 0.02% 372
2023
Q3 		$318K Buy
69,817
+35,026
+101% +$229K 0.01% 425
2023
Q2 		$245K Hold
34,791
– – 0.01% 461
2023
Q1 		$213K Hold
34,791
– – 0.01% 470
2022
Q4 		$222K Hold
34,791
– – 0.01% 447
2022
Q3 		$333K Hold
34,791
– – 0.01% 398
2022
Q2 		$384K Hold
34,791
– – 0.01% 384
2022
Q1 		$579K Buy
34,791
+7,453
+27% +$115K 0.02% 318
2021
Q4 		$522K Hold
27,338
– – 0.02% 353
2021
Q3 		$674K Hold
27,338
– – 0.02% 316
2021
Q2 		$711K Hold
27,338
– – 0.02% 318
2021
Q1 		$866K Hold
27,338
– – 0.03% 282
2020
Q4 		$1.27M Hold
27,338
– – 0.05% 281
2020
Q3 		$900K Sell
27,338
-3,468
-11% -$106K 0.04% 314
2020
Q2 		$846K Buy
30,806
+125
+0.4% +$4.11K 0.04% 320
2020
Q1 		$918K Sell
30,681
-12
-0% -$318 0.04% 304
2019
Q4 		$850K Buy
30,693
+5,487
+22% +$125K 0.02% 380
2019
Q3 		$459K Buy
+25,206
New +$557K 0.01% 493

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Curi RMB Capital's IOVA Position: Q2 2026 in Review

Curi RMB Capital sold out of Iovance Biotherapeutics (IOVA) in Q2 2026, closing a stake of 12,092 shares — an estimated $42.4K sold.

Curi RMB Capital first reported a position in IOVA in Q3 2019 and held it in 24 quarters. The position peaked at $1.27M in Q4 2020. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Curi RMB Capital reported no remaining Iovance Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Curi RMB Capital sold 12,092 Iovance Biotherapeutics shares in Q2 2026, an estimated $42.4K.
  • Curi RMB Capital first reported a position in Iovance Biotherapeutics in Q3 2019 and held it in 24 quarters.
  • Curi RMB Capital's Iovance Biotherapeutics position peaked at $1.27M in Q4 2020.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Curi RMB Capital's 13F filing for Q2 2026, filed 14 Aug 2026.